Comparative Pharmacology
Head-to-head clinical analysis: GRANISOL versus LOTRONEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRANISOL versus LOTRONEX.
GRANISOL vs LOTRONEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Granulocyte colony-stimulating factor (G-CSF) that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.
Selective serotonin 5-HT3 receptor antagonist; blocks serotonin action in the GI tract, reducing intestinal motility and visceral hypersensitivity.
375 mg/m2 intravenously over 1 hour every 3 weeks
1 mg orally once daily for 4 weeks, then may increase to 1 mg twice daily if tolerated; maximum 1 mg twice daily.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in hepatic impairment (up to 30 hours) and in the elderly.
The terminal elimination half-life is approximately 1.5 to 2 hours in healthy individuals. In patients with hepatic impairment, half-life may be prolonged.
Primarily hepatic metabolism with <5% excreted unchanged in urine; biliary/fecal elimination of metabolites accounts for ~60% of total clearance.
Alosetron is primarily eliminated via hepatic metabolism with subsequent renal excretion of metabolites. Approximately 73% of a dose is recovered in urine (mostly metabolites) and 24% in feces.
Category C
Category C
5-HT3 Receptor Antagonist
5-HT3 Receptor Antagonist